Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression

Oncogene volume 25, pages 6817–6830 (2006)Cite this article

Abstract

Abundant data support a key role for the transcription factor nuclear factor-κB (NF-κB) signaling pathway in controlling the initiation and progression of human cancer. NF-κB and associated regulatory proteins such as IκB kinase (IKK) are activated downstream of many oncoproteins and there is much evidence for the activation of NF-κB-dependent target genes in a variety of solid tumors and hematologic malignancies. This review focuses on the mechanisms by which the NF-κB pathway is activated in cancer and on the oncogenic functions controlled by activated NF-κB. Additionally, the effects of NF-κB activation in tumors relative to cancer therapy are also discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Adli M, Baldwin AS . (2006). J Biol Chem [Epub ahead of print].

  • Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J et al. (2003). Mol Biol Cell 14: 585–599.

  • Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB . (2002). Carcinogenesis 23: 143–150.

  • Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE . (2000). Mol Cell Biol 20: 5381–5391.

  • Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA . (2004). Oncogene 23: 8571–8580.

  • Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB . (2004). Biochem Pharmacol 67: 353–364.

  • Baldwin AS . (2001). J Clin Invest 107: 241–246.

  • Balkwill F, Charles KA, Mantovani A . (2005). Cancer Cell 7: 211–217.

  • Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. (1997). J Clin Invest 100: 2961–2969.

  • Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M et al. (2002). Leukemia 16: 2062–2071.

  • Biswas DK, Cruz AP, Gansberger E, Pardee AB . (2000). Proc Natl Acad Sci USA 97: 8542–8547.

  • Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al. (2004). Proc Natl Acad Sci USA 101: 10137–10142.

  • Bowman T, Garcia R, Turkson J, Jove R . (2000). Oncogene 19: 2474–2488.

  • Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F et al. (2006). Blood 107: 1156–1165.

  • Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. (1999). Cell 98: 295–303.

  • Bubici C, Papa S, Dean K, Franzoso G . (2006). Oncogene 25: 6731–6748.

  • Burstein E, Duckett CS . (2003). Curr Opin Cell Biol 15: 732–737.

  • Campbell KJ, Rocha S, Perkins ND . (2004). Mol Cell 13: 853–865.

  • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. (1999). Immunity 10: 105–115.

  • Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. (2005). Cancer Cell 8: 407–419.

  • Chen G, Bhojani MS, Heaford AC, Chang DC, Laxman B, Thomas DG et al. (2005). Proc Natl Acad Sci USA 102: 12507–12512.

  • Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E et al. (2006). Leukemia 20: 61–67.

  • Clevers H . (2004). Cell 118: 671–674.

  • Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS . (2000). Oncogene 19: 1123–1131.

  • Courtois G, Gilmore TD . (2006). Oncogene 25: 6831–6843.

  • Coussens LM, Werb Z . (2002). Nature 420: 860–867.

  • Cusack Jr JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al. (2001). Cancer Res 61: 3535–3540.

  • Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. (2003). Nature 421: 639–643.

  • Dhawan P, Richmond A . (2002). J Biol Chem 277: 7920–7928.

  • Dhawan P, Singh AB, Ellis DL, Richmond A . (2002). Cancer Res 62: 7335–7342.

  • Downward J . (2004). Semin Cell Dev Biol 15: 177–182.

  • Dutta J, Fan Y, Gupta N, Fan G, Gélinas C . (2006). Oncogene 25: 6800–6816.

  • Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC et al. (2005). Cancer Res 65: 11375–11383.

  • Farhana L, Dawson MI, Fontana JA . (2005). Cancer Res 65: 4909–4917.

  • Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari Jr AW et al. (2005). Cancer Res 65: 6294–6304.

  • Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R et al. (2005). Cancer Cell 7: 39–49.

  • Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin Jr AS . (1997). J Biol Chem 272: 24113–24116.

  • Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P et al. (2005). Blood 105: 804–811.

  • Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL et al. (2003). Clin Cancer Res 9: 346–354.

  • Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D . (1993). Genes Dev 7: 1354–1363.

  • Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ . (2000). J Immunol 164: 2200–2206.

  • Garcea G, Dennison AR, Steward WP, Berry DP . (2005). Pancreatology 5: 514–529.

  • Garcia MG, Alaniz L, Lopes EC, Blanco G, Hajos SE, Alvarez E . (2005). Leukemia Res 29: 1425–1434.

  • Gilmore TD . (2006). Oncogene 25: 6680–6684.

  • Gilmore TD and Herscovitch M . (2006). Oncogene 25: 6887–6899.

  • Grandage VL, Gale RE, Linch DC, Khwaja A . (2005). Leukemia 19: 586–594.

  • Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. (2004). Cell 118: 285–296.

  • Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q et al. (2004). J Biol Chem 279: 1615–1620.

  • Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS et al. (2005). Blood 105: 4163–4169.

  • Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T et al. (2004). Cancer Res 64: 8341–8348.

  • Hanahan D, Weinberg RA . (2000). Cell 100: 57–70.

  • Hanson JL, Hawke NA, Kashatus D, Baldwin AS . (2004). Cancer Res 64: 7248–7255.

  • Hayden MS, Ghosh S . (2004). Genes Dev 18: 2195–2224.

  • Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC et al. (2001). Oncogene 20: 4917–4925.

  • Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C . (2001). Blood 97: 2798–2807.

  • Hiscott J, Nguyen T-LA, Arguello M, Nakhaei P, Paz S . (2006). Oncogene 25: 6844–6867.

  • Ho WC, Dickson KM, Barker PA . (2005). Cancer Res 65: 4273–4281.

  • Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY et al. (2004). Cell 117: 225–237.

  • Huang S, Deguzman A, Bucana CD, Fidler IJ . (2000a). Clin Cancer Res 6: 2573–2581.

  • Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD et al. (2002). Am J Pathol 161: 125–134.

  • Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ . (2000b). Cancer Res 60: 5334–5339.

  • Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H et al. (2004a). J Clin Invest 114: 569–581.

  • Huber MA, Beug H, Wirth T . (2004b). Cell Cycle 3: 1477–1480.

  • Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T et al. (2003). Cancer Res 63: 8132–8137.

  • Jiang Y, Cui L, Yie TA, Rom WN, Cheng H, Tchou-Wong KM . (2001). Oncogene 20: 2254–2263.

  • Jin F, Liu X, Zhou Z, Yue P, Lotan R, Khuri FR et al. (2005). Cancer Res 65: 6354–6363.

  • Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L . (2003). FASEB J 17: 2115–2117.

  • Kalaitzidis D, Gilmore TD . (2005). Trends Endocrinol Metab 16: 46–52.

  • Karin M . (2006). Nature 441: 431–436.

  • Karin M, Cao Y, Greten FR, Li ZW . (2002). Nat Rev Cancer 2: 301–310.

  • Kashatus D, Cogswell P, Baldwin AS . (2006). Genes Dev 20: 225–235.

  • Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr AS . (2001). J Biol Chem 276: 22382–22387.

  • Kim HJ, Hawke N, Baldwin AS . (2006). Cell Death Differ 13: 738–747.

  • Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C et al. (2005a). Nature 434: 921–926.

  • Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG . (2005b). Cancer Res 65: 6312–6320.

  • Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G . (2003). Exp Hematol 31: 504–511.

  • Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C . (2000). Leukemia 14: 399–402.

  • Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G . (2003). Nature 424: 801–805.

  • Kucharczak J, Simmons MJ, Fan Y, Gélinas C . (2003). Oncogene 22: 8961–8982.

  • Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M et al. (2005). Clin Cancer Res 11: 28–40.

  • Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT . (2005). Cancer Res 65: 3828–3836.

  • Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM . (2003). Int J Cancer 105: 735–746.

  • Luo JL, Kamata H, Karin M . (2005). J Clin Invest 115: 2625–2632.

  • Maeda S, Kamata H, Luo JL, Leffert H, Karin M . (2005). Cell 121: 977–990.

  • Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R . (2006). Cell 125: 665–677.

  • Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C et al. (2003). Blood 102: 1028–1034.

  • Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ et al. (1997). Science 278: 1812–1815.

  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. (2002a). Proc Natl Acad Sci USA 99: 14374–14379.

  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. (2002b). Blood 99: 4525–4530.

  • Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I et al. (1999). Br J Cancer 79: 1025–1031.

  • Muerkoster S, Arlt A, Sipos B, Witt M, Grossmann M, Kloppel G et al. (2005). Cancer Res 65: 1316–1324.

  • Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML et al. (2004). Cancer Res 64: 1331–1337.

  • Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB . (2001). Oncogene 20: 7597–7609.

  • Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM . (2004). Leukemia Lymphoma 45: 1181–1184.

  • Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC . (2006). Proc Natl Acad Sci USA 103: 7264–7269.

  • Nakanishi C, Toi M . (2005). Nat Rev Cancer 5: 297–309.

  • Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW . (1997). Mol Cell Biol 17: 3629–3639.

  • Nakshatri H, Rice SE, Bhat-Nakshatri P . (2004). Oncogene 23: 7330–7344.

  • Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B et al. (2005). Oncogene 24: 419–430.

  • Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y et al. (2003). Oncogene 22: 7774–7780.

  • Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G et al. (2006). Nature 441: 106–110.

  • Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL et al. (2001). Br J Haematol 115: 279–286.

  • Niu J, Li Z, Peng B, Chiao PJ . (2004). J Biol Chem 279: 16452–16462.

  • Orlowski RZ, Baldwin Jr AS . (2002). Trends Mol Med 8: 385–389.

  • Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD . (2005). Cancer Res 65: 2076–2081.

  • Palmby TR, Abe K, Karnoub AE, Der CJ . (2004). Mol Cancer Res 2: 702–711.

  • Perkins ND . (2004). Trends Cell Biol 14: 64–69.

  • Perkins ND . (2006). Oncogene 25: 6717–6730.

  • Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE . (2001). Oncogene 20: 1287–1299.

  • Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. (2004). Nature 431: 461–466.

  • Rajkumar SV . (2003). Semin Hematol 40: 17–22.

  • Ramaswamy S, Perou CM . (2003). Lancet 361: 1576–1577.

  • Rayet B, Gélinas C . (1999). Oncogene 18: 6938–6947.

  • Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS . (1998). Genes Dev 12: 968–981.

  • Richardson PG, Hideshima T, Mitsiades C, Anderson K . (2004). Ann Med 36: 304–314.

  • Robe PA, tires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H et al. (2004). Clin Cancer Res 10: 5595–5603.

  • Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND . (2005). EMBO J 24: 1157–1169.

  • Romashkova JA, Makarov SS . (1999). Nature 401: 86–90.

  • Romieu-Mourez F, Kim DW, SHin SM, Demicco EG, Landesman-Bollag E, Seldin DC et al. (2002). Mol Cell Biol 23: 5738–5754.

  • Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P et al. (2001). Int J Radiat Oncol Biol Phys 50: 183–193.

  • Ryan KM, Ernst MK, Rice NR, Vousden KH . (2000). Nature 404: 892–897.

  • Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G et al. (2003). Mol Cell 12: 1413–1426.

  • Scheidereit C . (2006). Oncogene 25: 6685–6705.

  • Schneider G, Weber A, Zechner U, Oswald F, Friess HM, Schmid RM et al. (2006). Int J Cancer 118: 2405–2411.

  • Shishodia S, Aggarwal BB . (2004). Biochem Pharmacol 68: 1071–1080.

  • Shishodia S, Amin HM, Lai R, Aggarwal BB . (2005). Biochem Pharmacol 70: 700–713.

  • Shishodia S, Koul D, Aggarwal BB . (2004). J Immunol 173: 2011–2022.

  • Singh RK, Varney ML, Bucana CD, Johansson SL . (1999). Melanoma Res 9: 383–387.

  • Sitcheran R, Gupta P, Fisher PB, Baldwin AS . (2005). EMBO J 24: 510–520.

  • Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ . (2004). Mol Pharmacol 66: 1478–1490.

  • Sparmann A, Bar-Sagi D . (2004). Cancer Cell 6: 447–458.

  • Stark LA, Dunlop MG . (2005). Mol Cell Biol 25: 5985–6004.

  • Subhashini J, Mahipal SV, Reddanna P . (2005). Cancer Lett 224: 31–43.

  • Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L et al. (2005). Cancer Res 65: 5898–5906.

  • Takada Y, Bhardwaj A, Potdar P, Aggarwal BB . (2004). Oncogene 23: 9247–9258.

  • Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. (2005). Blood 105: 2324–2331.

  • Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I . (2002). Cancer Cell 1: 493–503.

  • Thiery JP . (2002). Nat Rev Cancer 2: 442–454.

  • Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G . (2003). Nature 424: 793–796.

  • Ueda Y, Richmond A . (2006). Pigment Cell Res 19: 112–124.

  • Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS . (1999a). Nat Med 5: 412–417.

  • Wang CY, Mayo MW, Baldwin Jr AS . (1996). Science 274: 784–787.

  • Wang W, Abbruzzese JL, Evans DB, Chiao PJ . (1999b). Oncogene 18: 4554–4563.

  • Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ . (1999c). Clin Cancer Res 5: 119–127.

  • Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH . (2006). Cancer Res 66: 2778–2784.

  • Webster GA, Perkins ND . (1999). Mol Cell Biol 19: 3485–3495.

  • Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin Jr AS . (2001). Mol Cell Biol 21: 8428–8436.

  • Yamamoto Y, Gaynor RB . (2001). J Clin Invest 107: 135–142.

  • Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL et al. (2005). Oncogene 24: 344–354.

  • Zaninoni A, Imperiali FG, Pasquini C, Zanella A, Barcellini W . (2003). Exp Hematol 31: 185–190.

  • Zhang JY, Green CL, Tao S, Khavari PA . (2004). Genes Dev 18: 17–22.

  • Zhou H, Du MQ, Dixit VM . (2005a). Cancer Cell 7: 425–431.

  • Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC . (2005b). Endocr Relat Cancer 12 (Suppl 1): S37–S46.

Download references

Acknowledgements

We are grateful for discussions with members of the Baldwin laboratory and with numerous scientists in the NF-κB and oncology fields. We especially thank Dr Noel Hawke for help with the preparation and design of figures. We regret being unable to reference all of the important published manuscripts on NF-κB and oncogenesis. We acknowledge scientific support from the NIH/NCI, the University of North Carolina Breast and GI SPORE programs, the Department of Defense Breast Cancer Program, and the Waxman Cancer Research Foundation (to ASB). DSB was supported by a fellowship from the International Association for the Study of Lung Cancer and a research grant from the Doctors Cancer Foundation.

Author information

Authors and Affiliations

  1. Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA

    D S Bassères & A S Baldwin

Authors
  1. D S Bassères
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A S Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A S Baldwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bassères, D., Baldwin, A. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817–6830 (2006). https://doi.org/10.1038/sj.onc.1209942

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209942

Keywords

This article is cited by

Search

Advanced search

Quick links